336 related articles for article (PubMed ID: 21047801)
1. Duration of etanercept treatment and reasons for discontinuation in a cohort of juvenile idiopathic arthritis patients.
Southwood TR; Foster HE; Davidson JE; Hyrich KL; Cotter CB; Wedderburn LR; Hull RG; Venning HE; Rahman JK; Cummins CL;
Rheumatology (Oxford); 2011 Jan; 50(1):189-95. PubMed ID: 21047801
[TBL] [Abstract][Full Text] [Related]
2. Factors associated with treatment response to etanercept in juvenile idiopathic arthritis.
Otten MH; Prince FH; Armbrust W; ten Cate R; Hoppenreijs EP; Twilt M; Koopman-Keemink Y; Gorter SL; Dolman KM; Swart JF; van den Berg JM; Wulffraat NM; van Rossum MA; van Suijlekom-Smit LW
JAMA; 2011 Dec; 306(21):2340-7. PubMed ID: 22056397
[TBL] [Abstract][Full Text] [Related]
3. Uveitis Events During Adalimumab, Etanercept, and Methotrexate Therapy in Juvenile Idiopathic Arthritis: Data From the Biologics in Pediatric Rheumatology Registry.
Foeldvari I; Becker I; Horneff G
Arthritis Care Res (Hoboken); 2015 Nov; 67(11):1529-35. PubMed ID: 25988824
[TBL] [Abstract][Full Text] [Related]
4. The risk of uveitis in patients with JIA receiving etanercept: the challenges of analysing real-world data.
Davies R; De Cock D; Kearsley-Fleet L; Southwood T; Baildam E; Beresford MW; Foster HE; Thomson W; Ramanan AV; Hyrich KL;
Rheumatology (Oxford); 2020 Jun; 59(6):1391-1397. PubMed ID: 31605484
[TBL] [Abstract][Full Text] [Related]
5. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study.
Hyrich KL; Lunt M; Watson KD; Symmons DP; Silman AJ;
Arthritis Rheum; 2007 Jan; 56(1):13-20. PubMed ID: 17195186
[TBL] [Abstract][Full Text] [Related]
6. Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients.
Gerloni V; Pontikaki I; Gattinara M; Fantini F
Ann Rheum Dis; 2008 Aug; 67(8):1145-52. PubMed ID: 17981916
[TBL] [Abstract][Full Text] [Related]
7. Drug survival of the first and second course of anti-tumour necrosis factor agents in juvenile idiopathic arthritis.
Tynjälä P; Vähäsalo P; Honkanen V; Lahdenne P
Ann Rheum Dis; 2009 Apr; 68(4):552-7. PubMed ID: 18467515
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness and safety of a second and third biological agent after failing etanercept in juvenile idiopathic arthritis: results from the Dutch National ABC Register.
Otten MH; Prince FH; Anink J; Ten Cate R; Hoppenreijs EP; Armbrust W; Koopman-Keemink Y; van Pelt PA; Kamphuis S; Gorter SL; Dolman KM; Swart JF; van den Berg JM; Wulffraat NM; van Rossum MA; van Suijlekom-Smit LW
Ann Rheum Dis; 2013 May; 72(5):721-7. PubMed ID: 22730374
[TBL] [Abstract][Full Text] [Related]
9. Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register.
Prince FH; Twilt M; ten Cate R; van Rossum MA; Armbrust W; Hoppenreijs EP; van Santen-Hoeufft M; Koopman-Keemink Y; Wulffraat NM; van Suijlekom-Smit LW
Ann Rheum Dis; 2009 May; 68(5):635-41. PubMed ID: 18413443
[TBL] [Abstract][Full Text] [Related]
10. Drug retention rates and relevant risk factors for drug discontinuation due to adverse events in rheumatoid arthritis patients receiving anticytokine therapy with different target molecules.
Sakai R; Tanaka M; Nanki T; Watanabe K; Yamazaki H; Koike R; Nagasawa H; Amano K; Saito K; Tanaka Y; Ito S; Sumida T; Ihata A; Ishigatsubo Y; Atsumi T; Koike T; Nakajima A; Tamura N; Fujii T; Dobashi H; Tohma S; Sugihara T; Ueki Y; Hashiramoto A; Kawakami A; Hagino N; Miyasaka N; Harigai M;
Ann Rheum Dis; 2012 Nov; 71(11):1820-6. PubMed ID: 22504558
[TBL] [Abstract][Full Text] [Related]
11. Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis.
Tynjälä P; Lindahl P; Honkanen V; Lahdenne P; Kotaniemi K
Ann Rheum Dis; 2007 Apr; 66(4):548-50. PubMed ID: 17068061
[TBL] [Abstract][Full Text] [Related]
12. Etanercept in methotrexate-resistant JIA-related uveitis.
Saeed MU; Raza SH; Goyal S; Cleary G; Newman WD; Chandna A
Semin Ophthalmol; 2014 Jan; 29(1):1-3. PubMed ID: 24175644
[TBL] [Abstract][Full Text] [Related]
13. Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry.
Horneff G; Schulz AC; Klotsche J; Hospach A; Minden K; Foeldvari I; Trauzeddel R; Ganser G; Weller-Heinemann F; Haas JP
Arthritis Res Ther; 2017 Nov; 19(1):256. PubMed ID: 29166924
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German Biologics JIA Registry.
Schmeling H; Minden K; Foeldvari I; Ganser G; Hospach T; Horneff G
Arthritis Rheumatol; 2014 Sep; 66(9):2580-9. PubMed ID: 24942886
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry.
Horneff G; De Bock F; Foeldvari I; Girschick HJ; Michels H; Moebius D; Schmeling H;
Ann Rheum Dis; 2009 Apr; 68(4):519-25. PubMed ID: 18413440
[TBL] [Abstract][Full Text] [Related]
16. Medically Significant Infections Are Increased in Patients With Juvenile Idiopathic Arthritis Treated With Etanercept: Results From the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study.
Davies R; Southwood TR; Kearsley-Fleet L; Lunt M; Hyrich KL;
Arthritis Rheumatol; 2015 Sep; 67(9):2487-94. PubMed ID: 25989609
[TBL] [Abstract][Full Text] [Related]
17. A follow-up study of patients with juvenile idiopathic arthritis who discontinued etanercept due to disease remission.
Pratsidou-Gertsi P; Trachana M; Pardalos G; Kanakoudi-Tsakalidou F
Clin Exp Rheumatol; 2010; 28(6):919-22. PubMed ID: 21205467
[TBL] [Abstract][Full Text] [Related]
18. Long-term safety of etanercept and adalimumab compared to methotrexate in patients with juvenile idiopathic arthritis (JIA).
Klotsche J; Niewerth M; Haas JP; Huppertz HI; Zink A; Horneff G; Minden K
Ann Rheum Dis; 2016 May; 75(5):855-61. PubMed ID: 25926155
[TBL] [Abstract][Full Text] [Related]
19. Twelve-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: Real-Life Data From a Local Registry.
Favalli EG; Pregnolato F; Biggioggero M; Becciolini A; Penatti AE; Marchesoni A; Meroni PL
Arthritis Care Res (Hoboken); 2016 Apr; 68(4):432-9. PubMed ID: 26556048
[TBL] [Abstract][Full Text] [Related]
20. Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis.
Giannini EH; Ilowite NT; Lovell DJ; Wallace CA; Rabinovich CE; Reiff A; Higgins G; Gottlieb B; Singer NG; Chon Y; Lin SL; Baumgartner SW;
Arthritis Rheum; 2009 Sep; 60(9):2794-804. PubMed ID: 19714630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]